IEAC Regimen followed by ASCT in the treatment of malignant lymphoma

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800016944

Enrollment

Unknown

Registered

2018-07-04

Start date

2018-09-01

Completion date

Unknown

Last updated

2018-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant lymphoma

Interventions

Case series:Idarubicin, Etoposide, Cytarabine,Cyclophosphamide (IEAC ) Regimen followed by ASCT

Eligibility

Sex/Gender

All

Age

16 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. diagnosed malignant lymphoma with the pathologically and immunohistochemically confirmed by tumor tissue; 2. intermediate or high subtype by PINKE risk-factor model with at least one measurable focus; 3. aged >= 16 years; 4. ECOG performance status of <3 with anticipated survival exceeding 3 months; 5. lab tests suitable for chemotherapy.

Exclusion criteria

Exclusion criteria: 1. relapsed or progressed patients treated by IEAC regime-contained chemotherapies in recent 6 months; 2. concurrent with HCV or HIV infection; 3. combination with pancreatitis; 4. concurrent with server infection needing ICU care; 5. with serious complications, such as fulminant DIC; 6. important organ failure; 7. pregnant or lactation period; 8. psychonosema; 9. allergy to the drug ofchemotherapy; 10. with secondary tumor need to under operation or chemotherapy in 6 months ahead; 11. in other correlated clinical trial.

Design outcomes

Primary

Measure	Time frame
Overall survival;	—

Secondary

Measure	Time frame
progress free survival;response rate;toxicity evaluation;	—

Countries

China

Contacts

Public ContactLi Wang

The First Affiliated Hospital of Chongqing Medical University

5640326@qq.com+86 18623015252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026